Proactiveinvestors United Kingdom RNS press releases https://www.biotech-capital.com Proactiveinvestors United Kingdom RNS press releases RSS feed en Thu, 20 Jun 2019 19:37:47 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Result of AGM ]]> https://www.biotech-capital.com/companies/rns/973/LSE20190603115214_14096266 Mon, 03 Jun 2019 11:52:14 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20190603115214_14096266 <![CDATA[RNS press release - Directorate Change, Annual Report & Notice of AGM ]]> https://www.biotech-capital.com/companies/rns/973/LSE20190418092011_14046196 Thu, 18 Apr 2019 09:20:11 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20190418092011_14046196 <![CDATA[RNS press release - Grant of Options ]]> https://www.biotech-capital.com/companies/rns/973/LSE20190405125504_14031110 Fri, 05 Apr 2019 12:55:04 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20190405125504_14031110 <![CDATA[RNS press release - Positive DSMC Review of Phase II Study for SNG001 ]]> https://www.biotech-capital.com/companies/rns/973/LSE20190314070007_14001505 Thu, 14 Mar 2019 07:00:07 +0000 https://www.biotech-capital.com/companies/rns/973/LSE20190314070007_14001505 <![CDATA[RNS press release - Preliminary results for the year ended 31 Dec 2018 ]]> https://www.biotech-capital.com/companies/rns/973/LSE20190225070006_13979572 Mon, 25 Feb 2019 07:00:06 +0000 https://www.biotech-capital.com/companies/rns/973/LSE20190225070006_13979572 <![CDATA[RNS press release - Update on LOXL2 programme with Pharmaxis ]]> https://www.biotech-capital.com/companies/rns/973/LSE20190117083140_13937970 Thu, 17 Jan 2019 08:31:40 +0000 https://www.biotech-capital.com/companies/rns/973/LSE20190117083140_13937970 <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.biotech-capital.com/companies/rns/973/LSE20181022100544_13837211 Mon, 22 Oct 2018 10:05:44 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20181022100544_13837211 <![CDATA[RNS press release - Part 2 start of Phase II COPD trial ]]> https://www.biotech-capital.com/companies/rns/973/LSE20181022070006_13836466 Mon, 22 Oct 2018 07:00:06 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20181022070006_13836466 <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.biotech-capital.com/companies/rns/973/LSE20181016150134_13831027 Tue, 16 Oct 2018 15:01:34 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20181016150134_13831027 <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.biotech-capital.com/companies/rns/973/LSE20181015084911_13828464 Mon, 15 Oct 2018 08:49:11 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20181015084911_13828464 <![CDATA[RNS press release - Result of General Meeting ]]> https://www.biotech-capital.com/companies/rns/973/LSE20181012110512_13827015 Fri, 12 Oct 2018 11:05:12 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20181012110512_13827015 <![CDATA[RNS press release - Result of General Meeting ]]> https://www.biotech-capital.com/companies/rns/973/LSE20181012102903_13826909 Fri, 12 Oct 2018 10:29:03 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20181012102903_13826909 <![CDATA[RNS press release - Result of Fundraise ]]> https://www.biotech-capital.com/companies/rns/973/LSE20180925175610_13804432 Tue, 25 Sep 2018 17:56:10 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20180925175610_13804432 <![CDATA[RNS press release - Proposed Fundraise to raise c.£2.9 million ]]> https://www.biotech-capital.com/companies/rns/973/LSE20180925130101_13803962 Tue, 25 Sep 2018 13:01:01 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20180925130101_13803962 <![CDATA[RNS press release - Half-year Report ]]> https://www.biotech-capital.com/companies/rns/973/LSE20180925130001_13803957 Tue, 25 Sep 2018 13:00:01 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20180925130001_13803957 <![CDATA[RNS press release - Positive SNG001 Biomarker Data in COPD Patients ]]> https://www.biotech-capital.com/companies/rns/973/LSE20180628070010_13696603 Thu, 28 Jun 2018 07:00:10 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20180628070010_13696603 <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.biotech-capital.com/companies/rns/973/LSE20180626130530_13694195 Tue, 26 Jun 2018 13:05:30 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20180626130530_13694195 <![CDATA[RNS press release - Result of AGM ]]> https://www.biotech-capital.com/companies/rns/973/LSE20180622114215_13690254 Fri, 22 Jun 2018 11:42:15 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20180622114215_13690254 <![CDATA[RNS press release - Synairgen Safety Data with SNG001 in COPD Patients ]]> https://www.biotech-capital.com/companies/rns/973/LSE20180622070005_13689600 Fri, 22 Jun 2018 07:00:05 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20180622070005_13689600 <![CDATA[RNS press release - Posting of Annual Report and Notice of AGM ]]> https://www.biotech-capital.com/companies/rns/973/LSE20180517070010_13644391 Thu, 17 May 2018 07:00:10 +0100 https://www.biotech-capital.com/companies/rns/973/LSE20180517070010_13644391